text.skipToContent text.skipToNavigation
  • Trade Only
  • Merlin-Partnership.svg
    In partnership with Williams Medical
Calling 01685 843676

Decapeptyl SR 3mg Vial POM x1

IDJ141, J141

Powder for suspension for injection, sustained release formulation.

Therapeutic indications
• Treatment of patients with locally advanced, non-metastatic prostate cancer, as an alternative to surgical castration.
• Treatment of metastatic prostate cancer.
• As adjuvant treatment to radiotherapy in patients with high-risk localised or locally advanced prostate cancer.
• As neoadjuvant treatment prior to radiotherapy in patients with high-risk localised or locally advanced prostate cancer.
• As adjuvant treatment to radical prostatectomy in patients with locally advanced prostate cancer at high risk of disease progression.
• Treatment of endometriosis.
• Treatment of uterine fibroids prior to surgery or when surgery is not appropriate.
• As adjuvant treatment in combination with tamoxifen or an aromatase inhibitor, of endocrine responsive early stage breast cancer in women at high risk of recurrence who are confirmed as pre-menopausal after completion of chemotherapy

Features

Nature and contents of container
• A type I, 5 mL capacity glass vial with an elastomer stopper and an aluminium cap containing the powder.
• Type I, 3 mL capacity glass ampoule containing 2 mL of the suspension vehicle.
• Box containing 1 vial and 1 ampoule with 1 syringe and 2 needles.

Special precautions for storage
• Do not store above 25°C. Keep the container in the outer carton.

Shelf life
• The product should be used immediately after reconstitution.

See more See less
Specs
Other
Presentation Vial
Decapeptyl
Presentation Vial
Pharma
Pack size 1
Presentation Vial
Reviews
Q&A
Downloads